Henry Gosebruch compensation by year
Neumora Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $337,500 | $700,000 | $94,231 |
| Bonus | $2,520,250 | $0 | $420,000 |
| Stock awards | $3,739,983 | $1,445,600 | $0 |
| Option awards | $14,929,223 | $2,251,200 | $86,263 |
| Non-equity incentive | $465,750 | $378,000 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $6,563 | $11,130 | $718,779 |
| Total | $21,999,269 | $4,785,930 | $1,319,273 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Neumora Therapeutics, Inc. DEF 14A filed January 1, 1900, accession 0001193125-26-161489, and prior-year filings.
How this page was built: the Neumora Therapeutics, Inc. filed document, accession 0001193125-26-161489. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 246,932 | $2,617,479 | — |
| RSU | 80,000 | $848,000 | — |
| Option | 1,316,969 | — | $6.36 |
| Option | 160,000 | — | $18.07 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Neumora Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Neumora Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joshua Pinto | President | $6,743,238 |
| Paul Berns | Chief Executive Officer | $4,562,461 |
| Bill Aurora | Chief Strategy Officer | $3,302,000 |
| Henry Gosebruch · this page | Former President and Chief Executive Officer | $1,319,273 |
Board service
Neumora Therapeutics board · FY2023How this board is paid
Company policy: Neumora Therapeutics pays directors a $40,000 cash retainer and $600,000 in Options. As stated in Neumora Therapeutics's FY2023 proxy.
Henry Gosebruch's compensation dossier, Neumora Therapeutics
You have read Henry Gosebruch's totals and holdings. The dossier adds each equity grant Neumora Therapeutics disclosed for Henry Gosebruch and Neumora Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Neumora Therapeutics compensation record
free company briefThis page is one person within Neumora Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Neumora Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Neumora Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.